Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
McKinsey
Baxter
Johnson and Johnson
Dow

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Perampanel - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for perampanel and what is the scope of patent protection?

Perampanel is the generic ingredient in one branded drug marketed by Eisai Inc and is included in two NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Perampanel has one hundred patent family members in thirty-three countries.

There are five drug master file entries for perampanel. One supplier is listed for this compound.

Summary for perampanel
International Patents:100
US Patents:2
Tradenames:1
Applicants:1
NDAs:2
Drug Master File Entries: 5
Suppliers / Packagers: 1
Bulk Api Vendors: 49
Clinical Trials: 55
Patent Applications: 114
DailyMed Link:perampanel at DailyMed
Recent Clinical Trials for perampanel

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of Mental Health (NIMH)Phase 1
Assistance Publique Hopitaux De MarseilleN/A
Mayo ClinicEarly Phase 1

See all perampanel clinical trials

Pharmacology for perampanel
Synonyms for perampanel
2-(2-oxo-1-phenyl-5-pyridin-2-ylpyridin-3-yl)benzonitrile
2-(6-Oxo-1-phenyl-1,6-dihydro-[2,3-bipyridin]-5-yl)benzonitrile
2-(6'-Oxo-1'-phenyl-1',6'-dihydro-[2,3'-bipyridin]-5'-yl)benzonitrile
2-(6'-oxo-1'-phenyl-1',6'-dihydro-2,3'-bipyridin-5'-yl)benzonitrile
2-(6'-Oxo-1'-Phenyl[1',6'-Dihydro[2,3'-Bipyridine]]-5'-Yl)benzonitrile
3-(2-Cyanophenyl)-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one
3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one
380917-97-5
3964AH
6ZP
AC-27375
AKOS016340421
AM806751
AOB87762
BC261877
BCP06505
BDBM50184410
Benzonitrile, 2-(1',6'-dihydro-6'-oxo-1'-phenyl(2,3'-bipyridin)-5'-yl)-
Benzonitrile, 2-(1',6'-dihydro-6'-oxo-1'-phenyl[2,3'-bipyridin]-5'-yl)-
C23H15N3O
CH-0056
CHEBI:71013
CHEMBL1214124
CS-1160
CTK1B5138
D08964
DB08883
DTXSID80191501
E 2007
E-2007
E2007
ER 155055-90
ER-155055-90
EX-A2128
Fycompa
Fycompa (TN)
GTPL7050
H821664NPK
HY-14745
KS-00000XJ4
MolPort-035-395-270
NCGC00378863-02
Perampane
Perampanel (USAN)
Perampanel [USAN:INN]
Perampanel(E2007 pound(c)
perampanelum
PRMWGUBFXWROHD-UHFFFAOYSA-N
SB16816
SCHEMBL194370
ST24039511
UNII-H821664NPK
W-5817
ZINC30691797

US Patents and Regulatory Information for perampanel

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc FYCOMPA perampanel TABLET;ORAL 202834-001 Oct 22, 2012 RX Yes No   Start Trial   Start Trial Y   Start Trial
Eisai Inc FYCOMPA perampanel TABLET;ORAL 202834-001 Oct 22, 2012 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Eisai Inc FYCOMPA perampanel TABLET;ORAL 202834-006 Oct 22, 2012 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Eisai Inc FYCOMPA perampanel SUSPENSION;ORAL 208277-001 Apr 29, 2016 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Eisai Inc FYCOMPA perampanel TABLET;ORAL 202834-002 Oct 22, 2012 RX Yes No   Start Trial   Start Trial Y   Start Trial
Eisai Inc FYCOMPA perampanel TABLET;ORAL 202834-005 Oct 22, 2012 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for perampanel

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1300396 300565 Netherlands   Start Trial PRODUCT NAME: PERAMPANEL, EEN ZOUT OF EEN HYDRAAT ERVAN; REGISTRATION NO/DATE: EU/1/12/776/001 .....016 20120723
1764361 PA2013017,C1764361 Lithuania   Start Trial PRODUCT NAME: PERAMPANELUM; REGISTRATION NO/DATE: EU/1/12/776/001 - EU/1/12/776/016, 2012 07 23 EU/1/12/776/017 - EU1/12/776/023 20121029
1300396 1290045-2 Sweden   Start Trial PRODUCT NAME: PERAMPANEL OCH SALTER OCH HYDRATER DAERAV; REG. NO/DATE: EU/1/12/776/001 20120723
1764361 PA2013017 Lithuania   Start Trial PRODUCT NAME: PERAMPANELUM; REGISTRATION NO/DATE: EU/1/12/776/001 - EU/1/12/776/016, 2012 07 23 EU/1/12/776/017 - EU1/12/776/023 20121029
1300396 C300565 Netherlands   Start Trial PRODUCT NAME: PERAMPANEL, EEN ZOUT OF EEN HYDRAAT ERVAN; REGISTRATION NO/DATE: EU/1/12/776/001 .....016 20120723
1300396 92113 Luxembourg   Start Trial PRODUCT NAME: PERAMPANEL ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (FYCOMPA)
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Medtronic
McKesson
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.